| 查看: 1423 | 回复: 7 | ||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | ||
honghao81_2007金虫 (小有名气)
|
[求助]
大家谁有USP35，帮忙查一下替莫唑胺(Temozolomide)的质量标准！先谢谢了。
|
|
| 可以发我邮箱honghao81_2000@163.com |
回复此楼» 猜你喜欢
澳门理工大学人工智能药物发现中心招收2026级博士研究生（申请-考核制）
已经有10人回复
-
锦州医科大学药用生物材料（专业代码1007Z1）招收调剂考生
已经有2人回复
-
药物学论文润色/翻译怎么收费?
已经有236人回复
-
26申博自荐
已经有12人回复
-
SUES&NERCN课题组接受硕士生调剂 (学硕1名+专硕1名)
已经有0人回复
-
SUES&NERCN课题组接受硕士生调剂 (学硕1名+专硕1名)
已经有0人回复
-
SUES&NERCN课题组接受硕士生调剂 (学硕1名+专硕1名)
已经有0人回复
-
求大佬收留
已经有0人回复
-
使用MolAICal生成小分子CHARMM力场拓扑和参数文件
已经有0人回复
-
扩散模型生成分子目前痛点，改进方向有哪些，论文创新性卡住了现在
已经有0人回复
-
求解答药物生成模型痛点以及创新点，扩散模型创新
已经有0人回复
痴夷子皮
版主 (文坛精英)
老痞
- DRDEPI: 8
- 应助: 2016 (讲师)
- 贵宾: 5.368
- 金币: 54487.3
- 散金: 41688
- 红花: 303
- 沙发: 1206
- 帖子: 32611
- 在线: 4303.7小时
- 虫号: 674536
- 注册: 2008-12-14
- 性别: GG
- 专业: 无神论
- 管辖: 人文社科
honghao81_2007
7楼2012-07-10 11:38:12
yugijiang
木虫 (著名写手)
- 应助: 661 (博士)
- 贵宾: 0.005
- 金币: 4018.4
- 红花: 11
- 帖子: 1790
- 在线: 178小时
- 虫号: 416091
- 注册: 2007-06-29
- 性别: GG
- 专业: 药物分析
【答案】应助回帖
★ ★ ★ ★ ★ ★
感谢参与，应助指数 +1
honghao81_2007: 金币+5, ★★★★★最佳答案 2012-07-09 15:18:02
痴夷子皮: 金币+1, 谢谢交流。欢迎常来哦。 2012-07-10 11:34:09
感谢参与，应助指数 +1
honghao81_2007: 金币+5, ★★★★★最佳答案 2012-07-09 15:18:02
痴夷子皮: 金币+1, 谢谢交流。欢迎常来哦。 2012-07-10 11:34:09
|
Add the following: Temozolomide (tem'' oh zoe' loe mide). C6H6N6O2194.15 Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-; 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide [85622-93-1]. DEFINITION Temozolomide contains NLT 98.0% and NMT 102.0% of C6H6N6O2, calculated on the as-is basis. [Caution—Temozolomide is cytotoxic. Great care should be taken to prevent inhaling particles of Temozolomide and exposure to the skin. ] IDENTIFICATION • A. Infrared Absorption 197K • B. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay. ASSAY [Note—Shake the solutions containing temozolomide to aid the dissolution. Do not sonicate. ] • Procedure Solution A: 0.5% (v/v) of glacial acetic acid in water Mobile phase: Solution A and methanol (96:4), containing 0.94 g/L of sodium 1-hexanesulfonate (0.005 M) Diluent: Dimethylsulfoxide. [Note—Use a freshly opened bottle. ] Standard solution: 1.0 mg/mL of USP Temozolomide RS in Diluent Sample solution: 1.0 mg/mL of Temozolomide in Diluent Chromatographic system (See Chromatography 621, System Suitability.) Mode: LC Detector: UV 270 nm Column: 4.6-mm × 15-cm; 5-µm packing L1 Flow rate: 1 mL/min Injection size: 10 µL System suitability Sample: Standard solution Suitability requirements Relative standard deviation: NMT 1.5% Tailing factor: NMT 1.9 Analysis Samples: Standard solution and Sample solution Calculate the percentage of C6H6N6O2 in the portion of Temozolomide taken: Result = (rU/rS) × (CS/CU) × 100 rU = = peak area from the Sample solution rS = = peak area from the Standard solution CS = = concentration of USP Temozolomide RS in the Standard solution (mg/mL) CU = = concentration of Temozolomide in the Sample solution (mg/mL) Acceptance criteria: 98.0%–102.0% calculated on the as-is basis IMPURITIES • Residue on Ignition 281: NMT 0.1% • Heavy Metals, Method II231: NMT 30 ppm • Organic Impurities [Note—Shake the solutions containing temozolomide to aid the dissolution. Do not sonicate. ] Mobile phase, Diluent, and Sample solution: Proceed as directed in the Assay. Standard solution: 2.0 µg/mL each of USP Temozolomide RS and USP Dacarbazine Related Compound A RS in Diluent System suitability solution: 0.5 µg/mL each of USP Temozolomide RS and USP Dacarbazine Related Compound A RS in Diluent, from the Standard solution Peak identification solution: Mix 5 mL of 0.1 N hydrochloric acid and 5 mL of 1.0 mg/mL of USP Temozolomide RS in Diluent. Heat the container for 1 h on a steam or boiling water bath. [Note—The preparation forms 2-azahypoxanthine, temozolomide acid, and dacarbazine related compound A. ] Chromatographic system: Proceed as directed in the Assay, using a run time of NLT 3.2 times the retention time of the temozolomide peak. System suitability Samples: Standard solution and System suitability solution Suitability requirements Resolution: NLT 2.0 between the temozolomide and dacarbazine related compound A peaks, Standard solution Relative standard deviation: NMT 10% for both dacarbazine related compound A and temozolomide peaks, System suitability solution Analysis Samples: Sample solution, Standard solution, and Peak identification solution Inject the Peak identification solution and identify the organic impurities according to the relative retention times given in Table 1. Calculate the percentage of dacarbazine related compound A (free base) in the portion of Temozolomide taken: Result = (rU/rS) × (CS/CU) × (Mr1/Mr2) × 100 rU = = peak area of dacarbazine related compound A from the Sample solution rS = = peak area of dacarbazine related compound A from the Standard solution CS = = concentration of USP Dacarbazine Related Compound A RS in the Standard solution (mg/mL) CU = = concentration of Temozolomide in the Sample solution (mg/mL) Mr1 = = molecular weight of dacarbazine related compound A (free base), 126.12 Mr2 = = molecular weight of dacarbazine related compound A (hydrochloride salt), 162.58 Calculate the percentage of any other individual impurity in the portion of Temozolomide taken: Result = (rU/rS) × (CS/CU) × (1/F) × 100 rU = = peak area of each impurity from the Sample solution rS = = peak area of temozolomide from the Standard solution CS = = concentration of USP Temozolomide RS in the Standard solution (mg/mL) CU = = concentration of Temozolomide in the Sample solution (mg/mL) F = = relative response factor for each individual impurity (see Table 1) Acceptance criteria: See Table 1. [Note—Disregard any unspecified impurity peaks less than 0.05%. ] Table 1 Name Relative Retention Time Relative Response Factor Acceptance Criteria, NMT (%) 2-Azahypoxanthinea 0.42 1.6 0.2 Temozolomide related compound Ab 0.53 1.0 0.5 Temozolomide acidc 0.84 1.0 0.1 Temozolomide 1.0 — — Dacarbazine related compound A (free base)d 1.37 — 0.1 Any unspecified impurity — 1.0 0.10 Total impurities — — 0.8 a 4a,5-Dihydro-4H-imidazo[4,5-d][1,2,3]triazin-4-one. b 4-Diazo-4H-imidazole-5-carboxamide. c 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid. d 5-Aminoimidazole-4-carboxamide. It is a free base of dacarbazine related compound A. SPECIFIC TESTS • Water Determination, Method Ic921: NMT 0.4% ADDITIONAL REQUIREMENTS • Packaging and Storage: Preserve in well-closed containers, and store at room temperature. • USP Reference Standards 11 USP Dacarbazine Related Compound A RS 5-Aminoimidazole-4-carboxamide hydrochloride. C4H6N4O·HCl 162.58 USP Temozolomide RS |
» 本帖已获得的红花（最新10朵）
2楼2012-07-09 14:03:22
honghao81_2007
金虫 (小有名气)
- 应助: 0 (幼儿园)
- 金币: 528.5
- 红花: 1
- 帖子: 156
- 在线: 28.2小时
- 虫号: 470422
- 注册: 2007-11-29
- 性别: GG
- 专业: 合成药物化学
3楼2012-07-09 14:44:51
honghao81_2007
金虫 (小有名气)
- 应助: 0 (幼儿园)
- 金币: 528.5
- 红花: 1
- 帖子: 156
- 在线: 28.2小时
- 虫号: 470422
- 注册: 2007-11-29
- 性别: GG
- 专业: 合成药物化学
4楼2012-07-09 14:55:28
100